Melanoma incidence is increasing, emphasizing the need for optimized management. Wide local excision (WLE) remains the standard for locoregional disease control. The main advantage of WLE is likely in removing microsatellite lesions near the primary tumour if fully excised. This study evaluates the incidence of residual tumour in WLE specimens using a large nationwide cohort. This to refine patient selection and support a more evidence-based approach to surgical management METHODS: A nationwide, population-based study was conducted using data from the Dutch Pathology Databank. Patients diagnosed with melanoma between 2000 and 2023 who had a completely resected tumour with diagnostic excision without reported microsatellite lesions. Among 44,628 patients undergoing WLE, 2.1 % had residual tumour. Residual tumour was significantly correlated with increased Breslow thickness, ulceration and nodular melanoma subtype. The incidence of residual tumour increased with advancing T stage, from 1.2 % in Tis to 11.2 % in T4b melanomas. The incidence of residual tumour following WLE for melanomas up to T2 is low (< 3 %). Our findings suggest that omission of the WLE for all melanomas up to T2 may well be considered.
Sentinel lymph node biopsy (SLNB) aims to stage patients. According to the 8th edition of the American Joint Committee on Cancer(AJCC) staging manual, patients with pT1b or pT2a melanoma can be eligible for adjuvant immunotherapy, however, only if they have a sentinel node (SN) tumour burden > 1 mm. This study aims to determine the percentage of patients with pT1b or pT2a that will become eligible for adjuvant immunotherapy following SLNB. A nationwide, population-based study was conducted using data from the Dutch Pathology Databank. Patients diagnosed with pT1b and pT2a melanoma between 2002 and 2023 were included. The primary endpoint was the number of SNs with a tumour burden > 1 mm. We identified 36,606 patients of who 16,042 underwent SLNB. SN positivity was 5 % for patients with pT1b melanoma, and 11 % for pT2a melanoma. A tumour burden > 1 mm was found in 1.5 % and 4.1 %, translating to a number needed to treat (NNT) of 69 for pT1b and 25 for pT2a. This nationwide study demonstrated a low incidence of positive SNs and minimal likelihood of significant clinical outcomes following SLNB. Given the high NNT to be eligible for adjuvant immunotherapy, SLNB may no longer be justified for pT1b melanoma. For patients with pT2a melanoma, SLNB should be considered carefully, balancing limited clinical benefits against potential risks.
Neoadjuvant immunotherapy is increasingly used in resectable stage III melanoma, with major pathological response (MPR) closely linked to improved outcomes. Predictive biomarkers are needed to identify responders and potentially allow surgical de-escalation. [¹⁸F]FDG-PET/CT is a non-invasive method to assess metabolic response, and the index lymph node (ILN) may reflect response of the entire nodal bain. This retrospective analysis of largely prospectively collected data included patients with resectable stage III melanoma treated with two cycles of neoadjuvant pembrolizumab at two Dutch melanoma centres. [¹⁸F]FDG-PET/CT was performed before and after treatment, with metabolic response classified using EORTC criteria. Volumetric PET parameters, metabolic tumour volume (MTV) and total lesion glycolysis (TLG), were analysed retrospectively. Pathological response was assessed according to INMC criteria. In patients undergoing therapeutic lymph node dissection, ILN response was compared with the entire nodal basin. Forty-seven patients initiated neoadjuvant pembrolizumab, and 39 underwent surgery. Twenty-four patients had evaluable PET/CT scans: complete metabolic response (CMR) in 12.5%, partial metabolic response (PMR) in 37.5%, stable disease in 16.7%, and progressive metabolic disease (PMD) in 33%. Overall, 59% achieved MPR. All patients with CMR achieved MPR; 64% with PMR achieved MPR, compared with only 12.5% with PMD. All patients with pathological complete or near-complete response showed reductions in both ΔTLG and ΔMTV. ILN response was fully concordant with total nodal basin response in all evaluable cases. Three patients who declined surgery after CMR remained recurrence-free during follow-up. Metabolic response on [¹⁸F]FDG-PET/CT, particularly CMR, strongly correlates with pathological response after neoadjuvant pembrolizumab. ILN response accurately reflects total nodal basin response, supporting response-adapted surgical strategies.
Neoadjuvant immunotherapy improves outcomes compared to adjuvant therapy in stage III melanoma and reduces costs when adjuvant therapy is omitted following a major pathological response (MPR). However, adjuvant therapy remains the sole systemic treatment for patients identified as stage III by sentinel lymph node biopsy (SLNB). Detecting nodal metastases prior to this procedure could be beneficial. We conducted a systematic review and meta-analysis to determine the accuracy of preoperative ultrasound and fine-needle aspiration cytology (FNAC) and the healthcare costs of implementing this strategy. PubMed, Embase, and Web of Science were searched up to March 21, 2025. Diagnostic cohort studies were included when preoperative ultrasound and/or FNAC were performed in patients with cutaneous melanoma eligible for SLNB, with histopathological confirmation. Studies that lacked individual patient-level diagnostic data were excluded. Two reviewers independently screened and extracted data. The pooled sensitivity and specificity were calculated using bivariate or univariate random-effects models. The associated healthcare costs for each strategy were calculated using the pooled estimates, costs of the procedure, therapies and follow-up. Of 1315 records screened, 19 diagnostic studies comprising 7396 patients were included. For ultrasound, pooled sensitivity was 33.6% (95% CI: 23.5–45.5%) and specificity 92.4% (87.3–95.6%). For FNAC, pooled sensitivity and specificity were 92.6% (15.9–99.9%) and 99.1% (96.6–99.8%). Most studies had unclear risk of bias in patient selection and index test domains, while applicability concerns were generally low. Substantial heterogeneity was observed across studies. Ultrasound-FNAC was estimated to detect approximately 31% (8/25.5) of nodal metastases preoperatively. Implementation of this strategy was cost saving across multiple scenarios where adjuvant immunotherapy was omitted following MPR. Implementation of ultrasound-FNAC prior to sentinel lymph node biopsy enables neoadjuvant immunotherapy and is cost saving, indicating potential value in routine clinical practice. None.
Background: Neoadjuvant immunotherapy has emerged as a superior strategy to adjuvant immunotherapy for patients with resectable, clinically detectable stage III melanoma, significantly improving event-free survival. In microscopic stage III disease, adjuvant immunotherapy is generally considered standard of care, although lack of survival benefit prompts re-evaluation of this sentinel lymph node biopsy (SLND) plus adjuvant therapy approach. Specifically, omission of SLNB may not only spare patients from surgery but also facilitate more effective systemic therapy, reduce the required number of immunotherapy doses, and potentially improve long-term oncological outcomes.Methods: Data from pivotal melanoma immunotherapy trials and MSLT-1 trails were used to model two clinical scenarios: (1) SLNB followed by adjuvant immunotherapy in patients with a positive sentinel lymph node, and (2) omission of SLNB with subsequent nodal recurrence treated using neoadjuvant anti–PD-1 plus anti–CTLA-4 immunotherapy. Distant metastasis–free survival (DMFS) was simulated using a Markov model.Findings: Omission of SLNB with treatment of nodal recurrence using neoadjuvant combination immunotherapy resulted in a 9–17 percentage point improvement in DMFS compared with the SLNB strategy followed by adjuvant immunotherapy in patients with a positive sentinel lymph node. The magnitude of benefit varied according to Breslow thickness.Interpretation: Omitting SLNB may improve oncological outcomes in patients with melanoma in the era of neoadjuvant immunotherapy. These findings provide a compelling rationale for an international randomized controlled trial to re-evaluate the role of SLNB within contemporary melanoma treatments.